ATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding KBR’s business, operations, and prospects, including allegations that: “despite the knowledge that the U.S. Department of Defense’s Transportation Command (TRANSCOM) had, for months, had material concerns with ...

ATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Jasper’s business, operations, and compliance policies, including allegations that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on ...

ATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Quanex Building Products Corporation (“Quanex” or the “Company”) (NYSE: NX). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Quanex’s business, operations, and prospects, including allegations that: (1) the Company’s procedures and policies regarding tooling and equipment maintenance in its Tyman, Mexico ...

ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). The lawsuit alleges Defendants represented that Cytokinetics expected approval from the U.S. Food and Drug Administration ("FDA") for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Miti ...

诉讼指控 - 股东集体诉讼指控VFC公司在2023年10月30日至2025年5月20日期间发布重大虚假或误导性陈述[1] - 公司未披露关于复兴计划（Reinvent）的重大不利信息 包括需要额外重置行动才能使Vans品牌恢复增长[1] - Vans品牌收入增长轨迹出现重大挫折 这与管理层关于复兴计划和Vans转型进展的评论相矛盾[1] 法律程序 - 申请成为首席原告的截止日期为2025年11月12日[3] - 诉讼涉及期间为2023年10月30日至2025年5月20日 投资者可联系Holzer & Holzer律师事务所[2] - Holzer & Holzer律所专门处理证券诉讼 自2000年以来已为股东追回数亿美元损失[3] 联系方式 - 投资者可通过电话(888) 508-6832或邮箱cholzer@holzerlaw.com联系Corey D Holzer律师[2][4] - 更多案件信息可通过律所网站www holzerlaw com/case/vfc/获取[2] - 该促销通讯由Holzer & Holzer律所付费发布 Corey Holzer为内容负责人[3]

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the "IPO†); and/or (ii) securities between February 2, 2024 and October 22, 2024. Alto describes itself as a "clinical-stage biopharmaceutical company in the U.S.†For more infor. ...

诉讼指控 - 股东集体诉讼指控Fly-E集团在2025年7月15日至8月14日期间做出 materially false and/or misleading statements 或未能披露 material adverse information [1] - 指控涉及公司锂电池技术、供应链变化、监管环境以及电动自行车和电动滑板车需求波动的潜在风险 [1] - 诉讼针对纳斯达克上市公司Fly-E Group Inc (NASDAQ: FLYE) 提出 [1] 股东参与信息 - 符合2025年7月15日至8月14日期间购入股票且遭受重大投资损失的股东可联系Corey D Holzer律师探讨法律权利 [2] - 联系渠道包括免费电话(888) 508-6832 或指定网站www holzerlaw com/case/fly-e-group/ [2][4] - 代理律所Holzer & Holzer LLC为ISS 2021-2023年度顶级证券诉讼律所 专精股东集体诉讼和衍生诉讼 [3] 律所背景 - Holzer & Holzer LLC自2000年成立以来在股东欺诈索赔案件中累计追回数亿美元资金 [3] - 该律所付费发布了本次促销通讯 Corey Holzer为内容负责律师 [3] - 更多律所信息可通过www holzerlaw com获取 [3]

ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Capricor’s four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. If you purchased shares of Capricor between October 9, 2024 and July 10, 2025, and exp ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Petco (WOOF) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Petco between January 14, 2021 and June 5, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder ri ...

诉讼核心指控 - 公司被指控在业务运营和前景方面做出重大虚假或误导性陈述或未能披露重大不利信息 [1] - 公司疫情相关顺风被指不可持续 其销售主要高端或高等级宠物食品的商业模式也被指不可持续 [1] - 公司差异化产品战略的强度被指被夸大 管理层被指控淡化问题的真实范围和严重性以及所需整改措施的规模 [1] - 公司缓解策略对可比销售指标的潜在负面影响被指被低估 公司实现可持续盈利增长的能力被指被夸大 [1] 诉讼时间范围 - 诉讼涉及在2021年1月14日至2025年6月5日期间购买公司股票的投资者 [2] 法律程序信息 - 申请成为首席原告的法院截止日期为2025年8月29日 [3] - 代理律所Holzer & Holzer, LLC在2021年、2022年和2023年被ISS评为顶级证券诉讼律所 [3] - 自2000年成立以来 该律所律师在为受欺诈和其他公司不当行为损害的股东追回数亿美元资金方面发挥了关键作用 [3]